UBS AM
WX

UBS AM’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

UBS AM’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-15,000
Closed -$648K – 2765
2015
Q3 		$648K Sell
15,000
-400
-3% -$16.9K ﹤0.01% 1889
2015
Q2 		$651K Sell
15,400
-25,800
-63% -$1.09M ﹤0.01% 1918
2015
Q1 		$1.6M Sell
41,200
-948,700
-96% -$36.5M ﹤0.01% 1457
2014
Q4 		$33.3M Sell
989,900
-256,100
-21% -$9.05M 0.03% 546
2014
Q3 		$43.6M Sell
1,246,000
-65,600
-5% -$2.25M 0.04% 439
2014
Q2 		$43.1M Buy
1,311,600
+260,800
+25% +$8.92M 0.04% 453
2014
Q1 		$38.7M Buy
1,050,800
+426,941
+68% +$15.7M 0.04% 464
2013
Q4 		$23.9M Buy
623,859
+569,959
+1,057% +$18M 0.03% 582
2013
Q3 		$1.48M Sell
53,900
-3,500
-6% -$82.9K ﹤0.01% 1355
2013
Q2 		$1.21M Buy
+57,400
New +$1.12M ﹤0.01% 1381

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

UBS AM's WX Position: Q4 2015 in Review

UBS AM sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 15,000 shares — an estimated $648K sold.

UBS AM first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $43.6M in Q3 2014. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • UBS AM reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • UBS AM sold 15,000 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $648K.
  • UBS AM first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • UBS AM's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $43.6M in Q3 2014.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on UBS AM's 13F filing for Q4 2015, filed 12 Feb 2016.